Candel therapeutics to participate in upcoming b. riley oncology conference

Needham, mass., jan. 12, 2023 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that paul peter tak, md, phd, fmedsci, president and chief executive officer, will participate in a virtual fireside chat at b. riley securities' 3rd annual oncology conference. details are as follows:
CADL Ratings Summary
CADL Quant Ranking